Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
05 janv. 2022 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference 5 January 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a...
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
01 déc. 2021 07h00 HE
|
Silence Therapeutics plc
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA)...
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
21 oct. 2021 08h30 HE
|
Silence Therapeutics plc
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication...
Silence Therapeutics to Host R&D Day on October 21, 2021
07 oct. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...
Silence Therapeutics Reports Half-Year 2021 Results
12 août 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics Reports Half-Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a)Silence to...
Notice of half year results
15 juil. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics Notice of Half Year Results 15 July 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and...
Silence Announces Mallinckrodt Exercise of Options for Two Additional Complement Targets
16 juil. 2020 07h00 HE
|
Silence Therapeutics
Silence Announces Mallinckrodt Exercise of Options for Two Additional Complement Targets Silence eligible to receive up to ~$700m milestones per targetDouble-digit royalties on net sales 16 July...
Silence Therapeutics Final results for the year ended 31 December 2019
14 avr. 2020 07h00 HE
|
Silence Therapeutics
Final results for the year ended 31 December 2019 April 14, 2020 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of...
Silence Therapeutics to Deliver Virtual Presentation at the Annual Needham Healthcare Conference and Announces Notice of Full Year Results
02 avr. 2020 07h00 HE
|
Silence Therapeutics
Silence Therapeutics to Deliver Virtual Presentation at the Annual Needham Healthcare Conference and Announces Notice of Full Year Results 2 April 2020 LONDON, Silence Therapeutics plc (LON: SLN)...
Silence Therapeutics Notice of results and R&D day
15 août 2019 07h00 HE
|
Silence Therapeutics
Silence Therapeutics Notice of Half Year Results and R&D Day August 15, 2019 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and...